Merus N.V. (MRUS) EPS Estimated At $-0.90

November 11, 2018 - By Alfred Lee

Analysts expect Merus N.V. (NASDAQ:MRUS) to report $-0.90 EPS on November, 29.They anticipate $0.05 EPS change or 5.26 % from last quarter’s $-0.95 EPS. After having $-0.48 EPS previously, Merus N.V.’s analysts see 87.50 % EPS growth. The stock decreased 6.65% or $0.98 during the last trading session, reaching $13.75. About 16,769 shares traded. Merus N.V. (NASDAQ:MRUS) has risen 26.53% since November 11, 2017 and is uptrending. It has outperformed by 10.91% the S&P500.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company has market cap of $311.20 million. The Company’s lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. It currently has negative earnings. The firm also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.

More news for Merus N.V. (NASDAQ:MRUS) were recently published by:, which released: “Merus to Present at the Jefferies 2018 London Healthcare Conference” on November 08, 2018.‘s article titled: “82 Biggest Movers From Yesterday” and published on November 01, 2018 is yet another important article.

Merus N.V. (NASDAQ:MRUS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: